Philadelphia Chromosome clinical trials
The registry lists 51 studies for Philadelphia Chromosome across more than 10 countries. 12 are recruiting or about to start. 12 of them are mainly about Philadelphia Chromosome (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-29.
Get an email when these change. Save the Philadelphia Chromosome studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Novartis Pharmaceuticals (10) · M.D. Anderson Cancer Center (5) · Assistance Publique - Hôpitaux de Paris (3) · Pfizer (3) · Il-Yang Pharm. Co., Ltd. (2) · Nanfang Hospital, Southern Medical University (2) · Institute of Hematology & Blood Diseases Hospital, China (2) · Takeda (2)
What is being tested here
Drugs under test in Philadelphia Chromosome studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Relcobatinib | 1 | 1 | 1 |
| Prednisone | 1 | 0 | 1 |
| Olverembatinib | 1 | 0 | 1 |
| Blinatumomab | 1 | 0 | 1 |
| Tucidinostat | 1 | 0 | 1 |
| Imatinib | 0 | 0 | 10 |
| Dasatinib | 0 | 0 | 4 |
| Asciminib | 0 | 2 | 2 |
| Azacitidine | 0 | 0 | 2 |
| Bosutinib | 0 | 1 | 2 |
Drug classes tested here Tyrosine kinase inhibitors (TKIs) 2 open · Antimetabolites 4
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 2
- Jan 2027A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia · M.D. Anderson Cancer Center
- Jul 2027CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies · National Cancer Institute (NCI)
Who these studies take
Of the 9 Philadelphia Chromosome studies recruiting now, 4 (44%) set no upper age limit and 5 (56%) stop at 75 or younger. 2 (22%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (11%) | 1 (11%) |
| 18 | 9 (100%) | 9 (100%) |
| 30 | 9 (100%) | 9 (100%) |
| 40 | 8 (89%) | 8 (89%) |
| 50 | 7 (78%) | 7 (78%) |
| 65 | 5 (56%) | 5 (56%) |
| 75 | 4 (44%) | 4 (44%) |
| 85 | 4 (44%) | 4 (44%) |
Across all 51 studies, recruiting or not: 35% stop at 75 or younger and 33% at 65; 25% take children; 0% are for women only and 0% for men only; 4% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 15, 2026.
Newly registered1
Studies
Recruiting first, then most recently updated. Showing 50 of 51. Browse all 51 → or search them.
- A Randomized Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIsNot yet recruitingNCT07905183Phase 3
- CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell MalignanciesRecruitingNCT05442515Phase 1/21 country
- A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid LeukemiaRecruitingNCT06401603Phase 11 country
- Metabolic Syndrome and Risk of Chronic Philadelphia Negative Myeloproliferative NeoplasmsNot yet recruitingNCT07814560
- Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.RecruitingNCT07074496Early Phase 11 country
- Asciminib Maintenance Therapy Following alloHCT or CAR T to Prevent Relapse in Adults With Ph+ALLRecruitingNCT07250087Phase 11 country
- Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CMLNot yet recruitingNCT07493408Phase 21 country
- Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL PatientsRecruitingNCT07039877Phase 21 country
- Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCTRecruitingNCT06061094Phase 21 country
- A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALLRecruitingNCT06220487Phase 21 country
- A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young AdultsRecruitingNCT02611492Phase 31 country
- Multicenter Trial Treatment of Philadelphia Chromosome Negative B-cell Acute Lymphoblastic Leukemia of Young AdultsRecruitingNCT026170041 country
- A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPActive, not recruitingNCT04971226Phase 329 countries
- A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)Active, not recruitingNCT05456191Phase 324 countries
- Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in ScotlandCompletedNCT053634881 country
- Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALLCompletedNCT03249870Phase 21 country
- ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase InhibitorTerminatedNCT04216563Phase 21 country
- Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic LeukemiaCompletedNCT02523976Phase 21 country
- A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic LeukemiaActive, not recruitingNCT03589326Phase 320 countries
- A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaTerminatedNCT04501614Phase 1/215 countries
- CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell MalignanciesCompletedNCT03448393Phase 11 country
- Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALLCompletedNCT05594784Phase 21 country
- Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP PatientsCompletedNCT05433532Phase 21 country
- Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaWithdrawnNCT04845035Phase 21 country
- Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in ChildrenCompletedNCT00287105Phase 21 country
- PETHEMA-BLIN-01/PET069014 (BLIN-01)TerminatedNCT03523429Phase 21 country
- Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)CompletedNCT035098961 country
- Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)CompletedNCT01724879Phase 21 country
- An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ LeukemiaCompletedNCT00171249Phase 25 countries
- An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-AlphaCompletedNCT00171223Phase 26 countries
- An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast CrisisCompletedNCT00171158Phase 24 countries
- A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT02130557Phase 326 countries
- Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)CompletedNCT01460498Phase 11 country
- Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND OptimisationCompletedNCT01243489Phase 41 country
- Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKICompletedNCT01602952Phase 1/23 countries
- TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic LeukemiaStatus unknownNCT01883219Phase 21 country
- Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid LeukemiaCompletedNCT00852566Phase 23 countries
- Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive LeukemiasCompletedNCT00261846Phase 227 countries
- Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic MalignanciesCompletedNCT01471067Phase 11 country
- Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic PhaseCompletedNCT01061177Phase 426 countries
- Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic LeukemiaCompletedNCT00154349Phase 2
- Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)CompletedNCT00428909Phase 11 country
- Effect of Food on Bioavailability of Modified Release Formulations of ImatinibCompletedNCT00420043Phase 1
- Effect of Food on Bioavailability of a Modified Release Formulation of ImatinibCompletedNCT00422825Phase 1
- Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia PatientsCompletedNCT01254188Phase 319 countries
- Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase PatientsCompletedNCT01511289Phase 34 countries
- Pegasys in Patients With Chronic Myeloid Leukemia (CML)TerminatedNCT01392170Phase 21 country
- Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic LeukemiaStatus unknownNCT01990807Phase 41 country
- Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL PositiveCompletedNCT00763763Phase 21 country
- Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)CompletedNCT00130195Phase 21 country